Brief: Relief Therapeutics Announces New Exclusive Definitive License Agreement For Olpruva With Acer Therapeutics
30/08/2023 21:27
Aug 30 (Reuters) - Relief Therapeutics Holding SA
RLFB.S :
* RELIEF THERAPEUTICS ANNOUNCES NEW EXCLUSIVE DEFINITIVE
LICENSE
AGREEMENT FOR OLPRUVA™ (ACER-001) WITH ACER THERAPEUTICS
* RELIEF THERAPEUTICS- PROVIDING UPFRONT PAYMENT OF $10
MILLION IN
CASH TO CO WITH POTENTIAL FOR AN ADDITIONAL $46.5 MILLION IN
MILESTONE AND ROYALTY PAYMENTS
* RELIEF THERAPEUTICS-ACER PROVIDING UPFRONT PAYMENT OF $10
MILLION IN CASH TO CO WITH POTENTIAL FOR ADDITIONAL $46.5
MILLION IN MILESTONE AND ROYALTY PAYMENTS
Source text for Eikon: ID:nEQ4wzrQBa
Further company coverage: RLFB.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31